Erratum to: Perspectives on treatment of metastatic castration-resistant prostate cancer(The Oncologist, (2013), 18, (558-567), 10.1634/theoncologist.2012-0478);Perspectives on treatment of metastatic castration-resistant prostate cancer

Oncologist

Volumn 18, Issue 5, 2013, Pages 558-567

  Merseburger, Axel S ^a   Bellmunt, Joaquim ^b   Jenkins, Cheryl ^c   Parker, Chris ^d   Fitzpatrick, John M ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HOSPITAL DEL MAR   (Spain)

^c Rocket Science Medical Communications   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Abiraterone acetate; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration resistant; Prostate cancer; Treatment

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; C REACTIVE PROTEIN; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; CYTOCHROME P450 17; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; LACTATE DEHYDROGENASE; MITOXANTRONE; ORTERONEL; PLACEBO; PLATINUM; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TASQUINIMOD; ZOLEDRONIC ACID;

ALGORITHM; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DRUG COST; DRUG DOSE REDUCTION; GENETIC HETEROGENEITY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84878198393     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0478errata     Document Type: Erratum

References (115)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Jemal A, Center M.M., De Santis C. et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781
4. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. Ann Oncol 2013;24:792-800
5. Heidenreich A, Bastian PJ, Bellmunt J et al. EuropeanAssociation of Urology: Guidelinesonprostate cancer 2012. Available at http://www.uroweb.org/ guidelines/online-guidelines/. Accessed April 5, 2013
6. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011;65: 1180-1192
7. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406
8. Palmberg C, Koivisto P, Kakkola L et al. Androgenreceptorgeneamplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000;164:1992-1995
9. Ford OH, III, Gregory CW, Kim D et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003;170:1817-1821
10. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39
11. Jiang Y, Palma JF, Agus DB et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010;56:1492-1495
12. Steinkamp MP, O'Mahony OA, BrogleyMet al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69:4434-4442
13. Buchanan G, Greenberg NM, Scher HI et al. Collocation ofandrogenreceptorgenemutations in prostate cancer. Clin Cancer Res 2001;7:1273-1281
14. Attard G, Swennenhuis JF, OlmosDet al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castrationresistant prostate cancer. Cancer Res 2009;69: 2912-2918
15. Bastus NC, Boyd LK, Mao X et al. Androgeninduced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010;70:9544-9548
16. Comuzzi B, Lambrinidis L, RogatschHet al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen-and anti-androgen-induced androgen receptor function. AmJ Pathol 2003;162:233-241
17. Culig Z, Comuzzi B, Steiner H et al. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004; 92:265-271
18. Ueda T, Mawji NR, Bruchovsky N et al. Ligandindependent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087-38094
19. Seaton A, Scullin P, Maxwell PJ et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008;29:1148-1156
20. Stope MB, Ronnau C, Schubert T et al. Transforming growth factor beta in prostate cancer: Cellular effects and basic molecular mechanisms. Urologe A 2013;52:378-383
21. Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295:115-120
22. Leon CG, Locke JA, Adomat HH et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010;70:390-400
23. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011;71:1656-1667
24. Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72:3457-3462
25. Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-16765
26. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216
27. Aryee MJ, Liu W, Engelmann JC et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci TranslMed 2013;5:169-170
28. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy.NEngl JMed2012;367:1187-1197
29. de Bono JS, Oudard S, OzgurogluMet al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147-1154
30. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-992
31. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
32. Parker C, Nilsson S, Heinrich D et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012;30:LBA4512
33. Tannock IF, de WR, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512
34. Petrylak DP, Tangen CM, HussainMHet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520
35. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245
36. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148
37. Rathkopf DE, Smith MR, de Bono JS et al. Updated interim analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in patients wiht metastatic castration-resistant prostate cancer without prior chemotherapy. J Clin Oncol 2013;31:5
38. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422
39. de Bono JS, Fizazi K, Saad F et al. Primary, secondary and quality of life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signalling inhibitor. J Clin Oncol 2012;30: 4519
40. Payne H, Bahl A, Mason M, Troup J, De BJ. Optimizing the care of patients withadvancedprostate cancer in the UK: Current challenges and future opportunities. BJU Int 2012;110:658-667
41. Fitzpatrick JM. Optimizing the management of prostate cancer in senior adults: call to action. The Oncologist 2012;17 (Suppl 1):1-3
42. Berruti A, Tucci M, Mosca A et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005;93:633-638
43. Mottet N, Bellmunt J, BollaMet al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-583
44. U.S. Food and Drug Administration. Clinical team leader review memo regarding SGE patient representative: Provenge, April 26, 2010. Available at http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ ucm213559.htm. Accessed April 5, 2013
45. Huber ML, Haynes L, Parker C et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104:273-279
46. Dendreon. Sipuleucel-T manufacturing demonstration study: NCT01477749. Available at http://www.clinicaltrials.gov/ct2/show/NCT01477749. Accessed April 5, 2013
47. Sonpavde G, Di LG, Higano CS et al. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: A critical analysis of the literature. Eur Urol 2012;61:639-647
48. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37(SUPPL.2):S15-S29
49. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593
50. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998; 17:331-336
51. Saad F, Gleason DM, Murray R et al. Arandomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468
52. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882
53. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978
54. Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advancedgenitourinary malignancies:Afocusonzoledronic acid. Ther Adv Urol 2012;4:85-101
55. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46
56. Fizazi K, CarducciM,SmithMet al.Denosumab versus zoledronic acid for treatment ofbonemetastases inmenwith castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-822
57. Vogelzang NJ, Parker C, Nilsson S et al. Updated analysis of radium-223 dichloride (RA-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) andbonemetastasesfromthephaseIIIrandomized trial (ALSYMPCA). J Clin Oncol 2013;31:11
58. Sartor O, Michels RM, Massard C et al. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. The Oncologist 2011;16:1487-1497
59. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8: 592-603
60. Eder JP, VandeWoudeGF, Boerner SA et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. ClinCancerRes2009;15:2207-2214
61. Hussain M, Smith MR, Sweeney C et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29:4516
62. Smith MR, Sweeney C, Rathkopf D.E. et al. Cabozantinib (XL184)in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results from a phase II nonrandomized expansion cohort. J Clin Oncol 2012;30:4513
63. de Bono JS, Smith MR, Rathkopf DE et al. Cabozantinib (XL184) at 40 mg in patients with metastatic castration-resistant prostate cancer: Results of a phase 2 non-randomized expansion cohort (NRE). Ann Oncol 2012;23:Abstract 8970
64. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:549-559
65. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-1755
66. Merseburger AS, Hennenlotter J, Simon P et al. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 2006;16:79-83
67. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-419
68. Rubenstein JH, Katin MJ, Mangano MM et al. Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 1997;20:376-380
69. Oudard S, Banu E, Scotte F et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormonerefractory prostate cancer patients. Ann Oncol 2007;18:1828-1833
70. Colloca G. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer:Areview. Cancer Treat Rev 2012;38:1020-1026
71. Scher HI, Halabi S, Tannock I et al. Design and endpoints of clinical trials for patients with progressive prostate cancerandcastrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26: 1148-1159
72. Sonpavde G, Pond GR, Berry WR et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012;30:607-613
73. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935
74. deBono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309
75. Miyamoto DT, Lee RJ, Stott SL et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012;2:995-1003
76. Halabi S, Small EJ, KantoffPWet al. Prognostic model for predicting survival inmenwith hormonerefractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237
77. Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007; 13:6396-6403
78. Armstrong AJ, Garrett-Mayer E, de WR et al. Prediction of survival following first-line chemotherapy inmenwith castration-resistant metastatic prostate cancer. Clin Cancer Res 2010;16:203-211
79. Ito M, Saito K, Yasuda Y et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 2011;78: 1131-1135
80. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 2008;26:2423-2424
81. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261
82. Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 2012;13:1676-1686
83. Nelson PS. Molecular states underlying androgen receptor activation:Aframework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012;30:644-646
84. Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30:637-643
85. Yap TA, Swanton C, de Bono JS. Personalization of prostate cancer prevention and therapy: Are clinically qualified biomarkers in the horizon?EPMA J 2012;3:3
86. Bourke L, Kirkbride P, Hooper R et al. Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer 2013;108:9-13
87. Scher HI, Morris MJ, Basch E et al. End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice. J Clin Oncol 2011;29:3695-3704
88. Sartor AO, Fitzpatrick JM. Urologists and oncologists: Adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int 2012;110:328-335
89. Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to firstline docetaxel: Assessment of clinical outcomes and predictive factors. Urology 2012;79:644-649.
90. Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010;46:1770-1772
91. Heck MM, Thalgott M, Retz M et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 2012; 110:E635-E640
92. Crawford ED, Flaig TW. Optimizing outcomes of advanced prostate cancer: Drug sequencing and novel therapeutic approaches. Oncology (Williston Park) 2012;26:70-77
93. Droz JP, Balducci L, Bolla M et al. Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010;106:462-469
94. Logothetis CJ, de Bono JS, Molina A et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COUAA-301 phase III study. J Clin Oncol 2011;29:4520
95. Nilsson S, Strang P, Aksnes AK et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678-686
96. Dror MM, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-920
97. Zengerling F, Streicher W, Schrader AJ et al. Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci 2012;13:11530-11542
98. Oh WK, Kantoff PW, Weinberg V et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705-3712
99. Aggarwal R, Weinberg V, Small EJ et al. The mechanism of action of estrogen in castration-resistant prostate cancer: Clues from hormone levels. Clin Genitourin Cancer 2009;7:E71-E76
100. Saad F, Hotte S, North S. et al. RandomizedphaseII trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. ClinCancerRes2011;17:5765-5773
101. Santegoets SJ, Stam AG, Lougheed SM et al. T cell profiling reveals high CD4(+)CTLA-4 (+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013;62:245-256
102. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial ofaPoxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-1105
103. Petrylak D, Gandhi JG, Clark WR et al. Aphase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. J Clin Oncol 2013;31:59
104. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-1503
105. Fizazi K, Massard C, James ND et al. ODM-21, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. J Clin Oncol 2013;31:65
106. Henry JY, Lu L, Adams M et al. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitroandin vivo. Prostate2012;72:856-867
107. Keizman D, Zahurak M, Sinibaldi V et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II doubleblinded, randomized study. Clin Cancer Res 2010; 16:5269-5276
108. Dahut WL, Aragon-Ching JB, Woo S et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49:650-660
109. Beer TM, Smith DC, Hussain A et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: A phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012;107:808-813
110. Araujo JC, Trudel GC, Saad F et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READYtrial. J ClinOncol 2013;31:LBA8
111. Miller K, Moul JW, Gleave M et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013 Feb5; doi:10.10381pcan.2013.2
112. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009;27:5431-5438
113. Kelly WK, Halabi S, Carducci M. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-1540
114. Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-2487
115. Migano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, doubleblind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-3679.